Latest & greatest articles for hiv

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hiv or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hiv and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hiv

81. Preexposure Prophylaxis for the Prevention of HIV Infection: US Preventive Services Task Force Recommendation Statement. Full Text available with Trip Pro

Preexposure Prophylaxis for the Prevention of HIV Infection: US Preventive Services Task Force Recommendation Statement. An estimated 1.1 million individuals in the United States are currently living with HIV, and more than 700 000 persons have died of AIDS since the first cases were reported in 1981. In 2017, there were 38 281 new diagnoses of HIV infection reported in the United States; 81% of these new diagnoses were among males and 19% were among females. Although treatable, HIV infection (...) has no cure and has significant health consequences.To issue a new US Preventive Services Task Force (USPSTF) recommendation on preexposure prophylaxis (PrEP) for the prevention of HIV infection.The USPSTF reviewed the evidence on the benefits of PrEP for the prevention of HIV infection with oral tenofovir disoproxil fumarate monotherapy or combined tenofovir disoproxil fumarate and emtricitabine and whether the benefits vary by risk group, population subgroup, or regimen or dosing strategy

2019 JAMA

82. Screening for HIV Infection: US Preventive Services Task Force Recommendation Statement. Full Text available with Trip Pro

Screening for HIV Infection: US Preventive Services Task Force Recommendation Statement. Approximately 1.1 million persons in the United States are currently living with HIV, and more than 700 000 persons have died of AIDS since the first cases were reported in 1981. There were approximately 38 300 new diagnoses of HIV infection in 2017. The estimated prevalence of HIV infection among persons 13 years and older in the United States is 0.4%, and data from the Centers for Disease Control (...) and Prevention show a significant increase in HIV diagnoses starting at age 15 years. An estimated 8700 women living with HIV give birth each year in the United States. HIV can be transmitted from mother to child during pregnancy, labor, delivery, and breastfeeding. The incidence of perinatal HIV infection in the United States peaked in 1992 and has declined significantly following the implementation of routine prenatal HIV screening and the use of effective therapies and precautions to prevent mother

2019 JAMA

83. Health technology assessment of a PrEP programme for populations at substantial risk of sexual acquisition of HIV

antiretroviral medications are taken by HIV-negative people prior to exposure to the virus to prevent infection. Once-daily oral tenofovir/emtricitabine, as a fixed dose combination tablet, has been licensed and available for use as PrEP in Ireland since 2016. Policy provision for PrEP is contained in the National Sexual Health Strategy 2015–2020, with Priority Action 3 calling for ‘the appropriate use of antiretroviral therapy in HIV prevention’. A PrEP programme provides PrEP medication along with holistic (...) Health technology assessment of a PrEP programme for populations at substantial risk of sexual acquisition of HIV Health technology assessment of a PrEP programme for populations at substantial risk of sexual acquisition of HIV 14 June 2019 Health technology assessment of a PrEP programme for populations at substantial risk of sexual acquisition of HIV Health Information and Quality Authority Page 2 of 257 Health technology assessment of a PrEP programme for populations at substantial risk

2019 Health Information and Quality Authority

84. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Full Text available with Trip Pro

Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. The level of evidence for HIV transmission risk through condomless sex in serodifferent gay couples with the HIV-positive partner taking virally suppressive antiretroviral therapy (ART) is limited compared with the evidence available for transmission risk in heterosexual (...) couples. The aim of the second phase of the PARTNER study (PARTNER2) was to provide precise estimates of transmission risk in gay serodifferent partnerships.The PARTNER study was a prospective observational study done at 75 sites in 14 European countries. The first phase of the study (PARTNER1; Sept 15, 2010, to May 31, 2014) recruited and followed up both heterosexual and gay serodifferent couples (HIV-positive partner taking suppressive ART) who reported condomless sex, whereas the PARTNER2

2019 Lancet

85. Monitoring Progress of Neurological and Functional Outcomes in the Paediatric HIV Cohort in the UK

). Encephalopathy and progress of human immunodeficiency virus disease in a cohort of children with perinatally acquired human immunodeficiency virus. Journal of Paediatrics, 135 (5), 808-812. Elliott-DeSorbo, D. K., Martin, S., & Wolters, P. L. (2009). Stressful life events and their relationship to psychological and medical functioning in children and adolescents with HIV infection. JAIDS Journal of Acquired Immune Deficiency Syndromes, 52, 364–370 Franklin, S., Lim, H. J., Rennie, K. M., Eastwood, D., Cuene (...) immunodeficiency virus (HIV-1) infection. Journal of child neurology, 26(11), 1355-1364. Innes, S., Lazarus, E., Otwombe, K., Liberty, A., Germanus, R., Janse Van Rensburg, A., Grobbelaar, N., Hurter, T., Eley, B., Violari, A. & Cotton, M. F. (2014). Early severe HIV disease precedes early antiretroviral therapy in infants: Are we too late?. Journal of the International AIDS Society, 17(1). Judd, A., Le Orevost, M, Melvin, D., Arenas-Pinto, A., Parrott, F., Winston, Al., Foster, C., Strurgeon, K., Rowson, K

2019 The Children's HIV Association

86. A cross-jurisdictional review of HIV testing intervals for population groups at high risk of HIV infection

for HIV testing of adults, adolescents, and pregnant women in health-care settings. Available from: . Morbidity and Mortality Weekly Report: Recommendations and Reports. 2006;55(14):1–17. Accessed April 24, 2019. Austin T, Traversy GP, Ha S, Timmerman K. Canadian and international recommendations on the frequency of HIV screening and testing: A systematic review. Canada Communicable Disease Report. 2016;42(8):161–8. Public Health Agency of Canada (PHAC). Human immunodeficiency virusHIV screening (...) and testing guide. 2014. Available from: . Accessed April 24, 2019. Institut national de santé publique du Québec, Sous-comité Optimiser le dépistage du VIH, Comité sur les infections transmissibles sexuellement et par le sang (ITSS). Optimiser le dépistage et le diagnostic de l’infection par le virus de l’immunodéficience humaine. 2011. Available from: . Accessed April 24, 2019. Gustafson R, Ogilvie G, Moore D, Kendall P. New HIV testing guidelines in BC. Available from: . BC Medical Journal. 2014;56(4

2019 Ontario HIV Treatment Network

87. Out-of-pocket costs associated with HIV in publicly funded high-income health care settings

Out-of-pocket costs associated with HIV in publicly funded high-income health care settings Out-of-pocket costs associated with HIV in publicly funded high-income health care settings | The Ontario HIV Treatment Network The Ontario HIV Treatment Network Out-of-pocket costs associated with HIV in publicly funded high-income health care settings Out-of-pocket costs associated with HIV in publicly funded high-income health care settings , , Question What out-of-pocket costs are associated (...) with aging among people living with HIV? Key take-home messages The aging of the people living with HIV in care is leading to increased HIV care costs (1). There is considerable inter-jurisdictional heterogeneity in the cost-sharing policies for antiretrovirals across Canada’s public drug programs (2). Out-of-pocket costs such as inadequate drug coverage, pharmacy dispensing fees, and clinic travel costs may affect treatment adherence and related health outcomes among people living with HIV (3, 4

2019 Ontario HIV Treatment Network

88. BHIVA guidelines on the management of HIV in pregnancy and postpartum

Appendix 1: PICO questions 101 Appendix 2: Summary of the modified GRADE system 104 BHIVA guidelines on the management of HIV in pregnancy and postpartum 6 References 104 Appendix 3: Drug dosing for infants 105 BHIVA guidelines on the management of HIV in pregnancy and postpartum 7 1. Scope and purpose The overall purpose of these guidelines is to provide guidance on best clinical practice in the treatment and management of women living with the human immunodeficiency virus (HIV) in the UK during (...) Section 7. HIV and hepatitis virus co-infections 12 Section 8. Obstetric management 14 Section 9. Neonatal management 16 Section 10. Postpartum management of women 18 2.2 Auditable outcomes 20 3. Introduction 21 3.1 UK prevalence and epidemiology of HIV in pregnancy, antenatal screening and risk of transmission 22 3.2 HIV infection in children 22 3.3 Reporting and long-term follow-up 23 3.4 National Study of HIV in Pregnancy and Childhood (NSHPC) 23 3.5 References 23 4. The psychosocial care of women

2019 British HIV Association

89. Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption. Full Text available with Trip Pro

Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption. Administration of a single broadly neutralizing human immunodeficiency virus (HIV)-specific antibody to HIV-infected persons leads to the development of antibody-resistant virus in the absence of antiretroviral therapy (ART). It is possible that monotherapy with UB-421, an antibody that blocks the virus-binding site on human CD4+ T cells, could induce sustained virologic suppression without induction of resistance (...) in HIV-infected persons after analytic treatment interruption.We conducted a nonrandomized, open-label, phase 2 clinical study evaluating the safety, pharmacokinetics, and antiviral activity of UB-421 monotherapy in HIV-infected persons undergoing analytic treatment interruption. All the participants had undetectable plasma viremia (<20 copies of HIV RNA per milliliter) at the screening visit. After discontinuation of ART, participants received eight intravenous infusions of UB-421, at a dose

2019 NEJM

90. Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection. Full Text available with Trip Pro

Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection. Emerging evidence suggests that risk of bacterial sexually transmitted infections (STIs) increases among gay and bisexual men following initiation of HIV preexposure prophylaxis (PrEP).To describe STI incidence and behavioral risk factors among a cohort of predominantly gay and bisexual men who use PrEP, and to explore changes in STI incidence following (...) PrEP commencement.The Pre-exposure Prophylaxis Expanded (PrEPX) Study, a multisite, open-label intervention study, was nested within the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance (ACCESS) clinic network. A total of 4275 participants were enrolled (July 26, 2016-April 1, 2018) in Victoria, Australia. Of these, 2981 enrolled at 5 ACCESS clinics (3 primary care, 1 sexual health, and 1 community-based HIV rapid testing service), had at least 1 follow-up visit, and were

2019 JAMA

91. Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study. Full Text available with Trip Pro

will lead to many fewer deaths among women, as well as fewer overall HIV transmissions. These results argue against a uniform policy of avoiding dolutegravir in women of child-bearing potential.National Institutes of Health, National Institute of Allergy and Infectious Diseases and Eunice Kennedy Shriver National Institute of Child Health and Human Development; Massachusetts General Hospital; and Harvard University Center for AIDS Research. (...) Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study. Dolutegravir is superior to efavirenz for HIV antiretroviral therapy (ART) but may be associated with an increased risk for neural tube defects (NTDs) in newborns if used by women at conception.To project clinical outcomes of ART policies for women of child-bearing potential in South Africa.Model of 3 strategies: efavirenz for all women of child

2019 Annals of Internal Medicine

92. Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (HIV-infected children) - Benefit assessment according to §35a Social Code Book V

and extent of added benefit 4 2 Table numbers start with “2” as numbering follows that of the full dossier assessment. Extract of dossier assessment A18-01 Version 1.0 EVG/COBI/FTC/TAF (HIV-infected children) 12 April 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - v - List of abbreviations Abbreviation Meaning ACT appropriate comparator therapy COBI cobicistat EVG elvitegravir FTC emtricitabine G-BA Gemeinsamer Bundesausschuss (Federal Joint Committee) HIV human immunodeficiency virus (...) HIV-1 human immunodeficiency virus type 1 IQWiG Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (Institute for Quality and Efficiency in Health Care) RCT randomized controlled trial SGB Sozialgesetzbuch (Social Code Book) TAF tenofovir alafenamide Extract of dossier assessment A18-01 Version 1.0 EVG/COBI/FTC/TAF (HIV-infected children) 12 April 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - 1 - 2 Benefit assessment 2.1 Executive summary of the benefit

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

93. Doravirine (Pifeltro) - for the treatment of adults infected with human immunodeficiency virus-1 (HIV-1)

Doravirine (Pifeltro) - for the treatment of adults infected with human immunodeficiency virus-1 (HIV-1) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity

2019 Health Canada - Drug and Health Product Register

94. Elvitegravir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1

Elvitegravir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1 Elvitegravir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1 - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Elvitegravir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1 Pharmacokinetic data (...) indicate exposure of elvitegravir boosted with cobicistat (Genvoya▼, Stribild) is lower during the second and third trimesters of pregnancy than postpartum. Low elvitegravir exposure may be associated with an increased risk of treatment failure and an increased risk of HIV-1 transmission to the unborn child, and therefore elvitegravir/cobicistat should not be used during pregnancy. Published 16 April 2019 From: Therapeutic area: , , Contents Advice for healthcare professionals: pharmacokinetic data

2019 MHRA Drug Safety Update

95. The efficacy of post-exposure prophylaxis (PEP) for HIV

and nonoccupational postexposure prophylaxis: Updated version, June 13, 2018. Canadian Medical Association Journal. 2017;189(47):E1448–e58. Kuhar DT, Henderson DK, Struble KA, Heneine W, Thomas V, Cheever LW, et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infection Control & Hospital Epidemiology. 2013;34(9):875–92. Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R (...) after. There was no difference in the rate at which PEP was offered to cases or controls after controlling for HIV transmission risk. However, the odds of HIV seroconversion among health care workers who had received PEP after occupational exposure was reduced by approximately 81%, compared to those who did not receive PEP (4). This study is considered the strongest example of the benefit of PEP in humans (1). Evidence from more recent studies suggests that the administration of antiretroviral

2019 Ontario HIV Treatment Network

96. The impact of location on implementation of HIV/STI prevention interventions among LGBTQ communities

The impact of location on implementation of HIV/STI prevention interventions among LGBTQ communities The impact of location on implementation of HIV/STI prevention interventions among LGBTQ communities | The Ontario HIV Treatment Network The Ontario HIV Treatment Network The impact of location on implementation of HIV/STI prevention interventions among LGBTQ communities The impact of location on implementation of HIV/STI prevention interventions among LGBTQ communities , , Questions What (...) is the impact of geographical location on implementation of HIV/STI prevention programs or interventions among LGBTQ communities? Key take-home messages The characteristics of a location, including segregation, community-level stigma, and infrastructural resources, may influence HIV service utilization and the HIV continuum of care among men who have sex with men (1). Implementation of HIV prevention interventions may be affected by whether a location is convenient, allows for anonymity, and makes one

2019 Ontario HIV Treatment Network

97. Yield and Efficiency of Novel Intensified Tuberculosis Case-Finding Algorithms for People Living with HIV Full Text available with Trip Pro

Yield and Efficiency of Novel Intensified Tuberculosis Case-Finding Algorithms for People Living with HIV The recommended tuberculosis (TB) intensified case finding (ICF) algorithm for people living with HIV (symptom-based screening followed by Xpert MTB/RIF [Xpert] testing) is insufficiently sensitive and results in unnecessary Xpert testing.To evaluate whether novel ICF algorithms combining C-reactive protein (CRP)-based screening with urine Determine TB-LAM (TB-LAM), sputum Xpert (...) , and/or sputum culture could improve ICF yield and efficiency.We compared the yield and efficiency of novel ICF algorithms inclusive of point-of-care CRP-based TB screening and confirmatory testing with urine TB-LAM (if CD4 count ≤100 cells/μl), sputum Xpert, and/or a single sputum culture among consecutive people living with HIV with CD4 counts less than or equal to 350 cells/μl initiating antiretroviral therapy in Uganda.Of 1,245 people living with HIV, 203 (16%) had culture-confirmed TB including 101 (49

2019 EvidenceUpdates

98. Should HIV-uninfected patients with Pneumocystis pneumonia be treated with corticosteroids?

Should HIV-uninfected patients with Pneumocystis pneumonia be treated with corticosteroids? Chiefs’ Inquiry Corner – March 17th, 2019 – Clinical Correlations Search Chiefs’ Inquiry Corner – March 17th, 2019 March 18, 2019 3 min read Propofol is a short-acting, intravenous sedative-hypnotic that is metabolized by the liver and excreted in the urine as conjugates of 2,6-diisopropyl-1,4 quinol. The pharmacokinetics of propofol favor its use for the induction/maintenance of anesthesia (...) with other causes of immunocompromise, especially in those with solid organ or liquid transplants, chronic steroid use, chemotherapeutics, and other immunosuppressive medications. As the use of immunosuppressive agents has increased in recent years, so has the rate of non-HIV associated Pneumocystis pneumonia (PCP). The use of steroids in HIV-infected patients with PCP has been well established, but the role of steroids in HIV-uninfected patients is much less clear. Patients with PCP who are not infected

2019 Clinical Correlations

99. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. Full Text available with Trip Pro

One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. Tuberculosis is the leading killer of patients with human immunodeficiency virus (HIV) infection. Preventive therapy is effective, but current regimens are limited by poor implementation and low completion rates.We conducted a randomized, open-label, phase 3 noninferiority trial comparing the efficacy and safety of a 1-month regimen of daily rifapentine plus isoniazid (1-month group) with 9 months of isoniazid alone (9 (...) -month group) in HIV-infected patients who were living in areas of high tuberculosis prevalence or who had evidence of latent tuberculosis infection. The primary end point was the first diagnosis of tuberculosis or death from tuberculosis or an unknown cause. Noninferiority would be shown if the upper limit of the 95% confidence interval for the between-group difference in the number of events per 100 person-years was less than 1.25.A total of 3000 patients were enrolled and followed for a median

2019 NEJM Controlled trial quality: predicted high

100. Does a Rehabilitation Program of Aerobic and Progressive Resisted Exercises Influence HIV-Induced Distal Neuropathic Pain? (Abstract)

Does a Rehabilitation Program of Aerobic and Progressive Resisted Exercises Influence HIV-Induced Distal Neuropathic Pain? Distal symmetrical polyneuropathy is a common neurological sequela after HIV, which leads to neuropathic pain and functional limitations. Rehabilitation programs with exercises are used to augment pharmacological therapy to relieve pain but appropriate and effective exercises are unknown. This study explored the safety and effect of moderate-intensity aerobic exercises (...) and progressive resisted exercises for HIV-induced distal symmetrical polyneuropathy neuropathic pain.A randomized pretest, posttest of 12 wks of aerobic exercise or progressive resisted exercise compared with a control. Outcome measures were assessed using the subjective periphery neuropathy, brief peripheral neuropathy screening, and numeric pain rating scale. Pain was assessed at baseline, 6 and 12 wks. Data between groups were compared using Kruskal-Wallis, Mann-Whitney U test, and within-groups Friedman

2019 American journal of physical medicine & rehabilitation Controlled trial quality: uncertain